Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
Top Cited Papers
Open Access
- 16 March 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (7), 1129-1136
- https://doi.org/10.1038/sj.bjc.6605611
Abstract
Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure. We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed. Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10, increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens. The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.Keywords
This publication has 62 references indexed in Scilit:
- Cell-Mediated Immune Responses to Human Papillomavirus 16 E6 and E7 Antigens as Measured by Interferon Gamma Enzyme-Linked Immunospot in Women With Cleared or Persistent Human Papillomavirus InfectionInternational Journal of Gynecologic Cancer, 2009
- Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 16The Journal of Immunology, 2009
- Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunityVaccine, 2009
- Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cellsVaccine, 2009
- Association of cervical cancer with the presence of CD4+regulatory T cells specific for human papillomavirus antigensProceedings of the National Academy of Sciences of the United States of America, 2007
- Correlates of sexual function following vulvar excisionGynecologic Oncology, 2007
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- The first complete chloroplast genome sequence of a lycophyte, Huperzia lucidula (Lycopodiaceae)Gene, 2005
- Functional Attributes of Mucosal Immunity in Cervical Intraepithelial Neoplasia and Effects of HIV InfectionCancer Research, 2004
- Photodynamic Therapy of Vulvar Intraepithelial Neoplasia III Using Topically Applied 5-Aminolevulinic AcidGynecologic Oncology, 2001